LRRC15 dependent transforming growth factor beta R2 - Bonum Therapeutics
Alternative Names: LRRC15-TGFβR2Latest Information Update: 02 Feb 2024
At a glance
- Originator Bonum Therapeutics
- Class Antineoplastics; Cytokines
- Mechanism of Action Transforming growth factor beta receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Research Cancer
Most Recent Events
- 09 Jan 2024 Early research in Cancer in USA (Parenteral) (Bonum Therapeutics pipeline, January 2024)
- 31 Dec 2023 LRRC15 dependent transforming growth factor beta R2 - Bonum Therapeutics is available for licensing as of 31 Dec 2023. https://bonumtx.com/partnerships/